Aclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024. In the quarter to June 2026, revenue fell 8.33%, EPS fell 15.4% and free cash flow fell 98.8%, each against the same quarter a year earlier.
Follow ACRS
Aclaris Therapeutics, Inc. (ACRS) EV/Sales
As of 16 October 2026, Aclaris Therapeutics, Inc. (ACRS) trades at a EV/Sales of 47.1×. Over the past ten years it has ranged from −10.5× (August 2019) to 200× (April 2021); the current reading is higher than 77% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 36.9× | 677.92% |
| FY2024 | 4.7× | — |
| FY2023 | −1.1× | — |
| FY2022 | 26.1× | (72.63%) |
| FY2021 | 95.3× | 166.49% |
| FY2020 | 35.8× | 2,118.76% |
| FY2019 | 1.6× | (91.66%) |
| FY2018 | 19.3× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 82.0× | 76.75% |
| Mar 2026 | 46.4× | 25.73% |
| Dec 2025 | 36.9× | 293.17% |
| Sep 2025 | 9.4× | 85.47% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MNPR Monopar Therapeutics Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 1.9× |
| CTMX CytomX Therapeutics, Inc. compare | 9.3× |
| ACRS Aclaris Therapeutics, Inc. | 47.1× |
| ENTX Entera Bio Ltd. compare | 541× |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | 759× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)